Sun Pharma Recalls Over 40,000 Bottles of Antidepressant in US
Sun Pharmaceutical Industries Ltd is recalling 41,127 bottles of antidepressant venlafaxine hydrochloride in the United States after the drug failed to dissolve properly, the US Food and Drug Administration (FDA) said.
The voluntary recall was begun by Caraco Pharmaceutical Laboratories Ltd, a unit of Sun Pharma, in June, and was classified by the US health regulator as Class II, meaning that use of or exposure to the drug may cause temporary or medically reversible adverse health consequences.
"Stability results found the product did not meet the drug release dissolution specifications," the FDA said in a post on its website on Friday.
Dissolution tests are commonly conducted to help predict how a drug performs inside the body.
Sun Pharma manufactured the drug at its plant in Gujarat. A company spokesman in Mumbai declined comment.
The company's recall of venlafaxine hydrochloride comes three months after Pfizer Inc said it was pulling 104,000 bottles of the same drug, which the US company sells under the brand Effexor XR, after a pharmacist reported that one of the bottles contained a heart drug.
Sun Pharma also began a recall of 200 vials of the chemotherapy drug gemcitabine in the United States in April due to a lack of assurance of sterility.
Separately, in January, the company pulled 2,528 bottles of its generic version of the diabetes drug Glumetza.
Copyright @ Thomson Reuters 2014
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
